CLVT

Clarivate is a subscription-heavy provider of IP, academic and life-sciences intelligence that throws off real cash — $629M of operating cash flow and ~$366M of free cash flow (after $263M capex) in FY2025 — yet screens as 'losing money' because $757M of D&A (largely amortization of acquired intangibles) drives a $201M GAAP net loss. The market is pricing the equity for distress: $2.19 a share, a $1.40B cap and 0.6x sales. On a pure equity basis that looks like deep value, and the loss is shrinking fast (net loss improved 68% YoY off a $7.51B accumulated-deficit hole carved out by prior goodwill write-downs). Management points to a 92.5% renewal rate (up from 91.9%) and organic ACV up 1.8% on better pricing — evidence the core subscription base is sticky.

The problem is the top line and the balance sheet. Revenue has now fallen four years running — $2.66B (2022) to $2.63B to $2.56B to $2.46B — and the MD&A concedes total ACV actually declined 1.0% as the company winds down certain product groups. So the 1.8% organic ACV figure is flattered by pricing while the contracted book is still shrinking. Against that backdrop sits a leveraged-rollup capital structure: ~$5.5B of debt (long-term debt was $5.46B as of the latest disclosed figure), only $329M of cash, and current liabilities ($1.57B) exceeding current assets ($1.31B) for a sub-1 current ratio. On an enterprise-value basis the 'cheapness' largely evaporates — EV is roughly $6.6B, or ~18x free cash flow, for a business with no organic growth.